Jerry Durso is recorded as Board Member at Altimmune, Inc. (ALT) since February 27, 2025 and CEO at Altimmune, Inc. (ALT). Altimmune, Inc. reported in an 8-K filed December 1, 2025 that Jerry Durso was appointed President and Chief Executive Officer, effective January 1, 2026. Altimmune, Inc. reported in an 8-K filed February 27, 2025 that Jerry Durso was appointed Board of Directors. Jerry Durso has spoken on 3 earnings calls and 2 other investor events across 1 company, most recently for Altimmune, Inc. on September 10, 2026. Altimmune, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Altimmune, Inc. includes Jerome Durso (CEO and Board Member), Vipin K. Garg (CEO), William Enright (CEO) and 7 others.
“Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman.”
Altimmune, Inc. Form 8-K, filed December 1, 2025
· Read the filing
“The Company strengthened its Board of Directors with the appointments of pharmaceutical industry veterans Teri Lawver and Jerry Durso”
Altimmune, Inc. Form 8-K, filed February 27, 2025
· Read the filing
Jerry Durso on recent calls
“So at Altamune, we're a company focused on liver disease. I've been the CEO since the beginning of 26. The main focus of our efforts is around pembidutide, which is a balanced glucagon GLP agonist, and again, we think is well positioned for liver diseases based on the overall clinical profile that's evolved.”
“Pembidutide is our foundation, and our confidence and conviction in its potential continues to strengthen with the growing body of clinical evidence. We're building momentum across our Pembidutide franchise and are excited for the future.”
“So it was Pemba Dewtide, the asset that really attracted me to Altamute. Last year, I had been approached first to join the board, and having spent a long time in liver disease and in MASH specifically previously, for me, I looked at the opportunity, the potential.”
“Good morning, everyone, and thank you for joining us today for our fourth quarter financial results and corporate update. As this is my first earnings call since joining Alt-Immune as CEO in January, I'd like to start with some comments to reinforce why I'm excited about the opportunities ahead of us with Pembedutide.”
